- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- monomer
- Ligands
- 1 x GAW: 2-[3,5-bis(trifluoromethyl)phenyl]-~{N},2-dimethyl-~{N}-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide(Non-covalent)
- 1 x CIT: CITRIC ACID(Non-functional Binders)
- 9 x OLA: OLEIC ACID(Non-functional Binders)(Non-covalent)
OLA.3: 2 residues within 4Å:- Ligands: OLA.4, OLC.12
No protein-ligand interaction detected (PLIP)OLA.4: 11 residues within 4Å:- Chain A: G.213, Y.216, T.217, G.220, I.221, R.224, V.439
- Ligands: OLA.3, OLC.12, PEG.31, PEG.41
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:Y.216, A:V.439
- Salt bridges: A:R.224
OLA.5: 7 residues within 4Å:- Chain A: F.103, K.106, F.107, F.110, F.163, G.166, Y.167
7 PLIP interactions:7 interactions with chain A- Hydrophobic interactions: A:F.103, A:K.106, A:F.110, A:F.163, A:Y.167
- Hydrogen bonds: A:G.166
- Salt bridges: A:K.106
OLA.6: 6 residues within 4Å:- Chain A: V.51, A.504, F.505, C.507
- Ligands: PEG.27, OLC.40
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:V.51, A:F.505
OLA.7: 6 residues within 4Å:- Chain A: Y.121, T.124, A.125, I.154, L.157, L.203
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:Y.121, A:Y.121, A:T.124, A:I.154, A:L.157, A:L.203
OLA.8: 5 residues within 4Å:- Chain A: Y.131, H.136, Y.214
- Ligands: OLC.13, OLC.15
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:Y.214
OLA.9: 0 residues within 4Å:- (No contacts)
No protein-ligand interaction detected (PLIP)OLA.10: 4 residues within 4Å:- Chain A: T.441, L.478, Y.485
- Ligands: OLC.12
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:T.441, A:L.478, A:Y.485
OLA.11: 3 residues within 4Å:- Chain A: V.195, I.198, C.199
2 PLIP interactions:2 interactions with chain A- Hydrophobic interactions: A:V.195, A:I.198
- 7 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)
OLC.12: 14 residues within 4Å:- Chain A: G.220, L.223, R.224, R.429, K.433, I.436, V.437, C.440, T.441, I.444
- Ligands: OLA.3, OLA.4, OLA.10, PEG.41
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:I.436, A:I.436, A:V.437, A:I.444
- Hydrogen bonds: A:R.224, A:R.429, A:R.429
- Salt bridges: A:R.224
OLC.13: 9 residues within 4Å:- Chain A: F.128, M.132, H.136, Q.139, L.207, Y.214
- Ligands: OLA.8, OLC.15, PEG.36
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:F.128, A:F.128, A:L.207, A:Y.214
- Salt bridges: A:H.136
OLC.14: 8 residues within 4Å:- Chain A: I.32, A.36, T.40, V.87, F.90, T.91, V.94, H.95
4 PLIP interactions:4 interactions with chain A- Hydrophobic interactions: A:I.32, A:V.87, A:F.90, A:T.91
OLC.15: 8 residues within 4Å:- Chain A: Y.131, I.135, H.136, Y.214, V.218
- Ligands: OLA.8, OLC.13, OLC.39
4 PLIP interactions:4 interactions with chain A- Hydrophobic interactions: A:I.135, A:V.218, A:V.218
- Salt bridges: A:H.136
OLC.16: 6 residues within 4Å:- Chain A: V.72, N.73, F.76, K.148, I.151, W.155
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:F.76, A:W.155, A:W.155
OLC.39: 8 residues within 4Å:- Chain A: I.135, P.137, I.221, T.222, F.350, D.374
- Ligands: OLC.15, PEG.25
6 PLIP interactions:6 interactions with chain A- Hydrophobic interactions: A:I.221, A:T.222, A:F.350, A:F.350
- Hydrogen bonds: A:I.135, A:D.374
OLC.40: 6 residues within 4Å:- Chain A: V.51, W.55, H.503, A.504, R.506
- Ligands: OLA.6
4 PLIP interactions:4 interactions with chain A- Hydrophobic interactions: A:V.51, A:W.55
- Hydrogen bonds: A:H.503, A:R.506
- 24 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
PEG.17: 6 residues within 4Å:- Chain A: M.174, P.175, S.176, R.177, V.179
- Ligands: PEG.37
Ligand excluded by PLIPPEG.18: 3 residues within 4Å:- Chain A: F.103, K.106
- Ligands: CIT.2
Ligand excluded by PLIPPEG.19: 3 residues within 4Å:- Chain A: V.88, Y.100
- Ligands: PEG.24
Ligand excluded by PLIPPEG.20: 3 residues within 4Å:- Chain A: L.160, F.163
- Ligands: PEG.33
Ligand excluded by PLIPPEG.21: 4 residues within 4Å:- Chain A: A.474, I.475, W.477, L.478
Ligand excluded by PLIPPEG.22: 4 residues within 4Å:- Chain A: I.382, E.391, N.394, A.395
Ligand excluded by PLIPPEG.23: 3 residues within 4Å:- Chain A: T.171, V.178
- Ligands: CIT.2
Ligand excluded by PLIPPEG.24: 5 residues within 4Å:- Chain A: F.84, F.103, Y.104, F.107
- Ligands: PEG.19
Ligand excluded by PLIPPEG.25: 4 residues within 4Å:- Chain A: I.134, D.374, F.421
- Ligands: OLC.39
Ligand excluded by PLIPPEG.26: 2 residues within 4Å:- Chain A: Q.31, W.35
Ligand excluded by PLIPPEG.27: 2 residues within 4Å:- Chain A: V.48
- Ligands: OLA.6
Ligand excluded by PLIPPEG.28: 3 residues within 4Å:- Chain A: S.426, R.429, K.430
Ligand excluded by PLIPPEG.29: 4 residues within 4Å:- Chain A: P.448, I.451, L.455, I.475
Ligand excluded by PLIPPEG.30: 3 residues within 4Å:- Chain A: T.45, V.48, F.501
Ligand excluded by PLIPPEG.31: 4 residues within 4Å:- Chain A: G.213, Y.214, T.217
- Ligands: OLA.4
Ligand excluded by PLIPPEG.32: 4 residues within 4Å:- Chain A: S.251, G.254, M.255, D.256
Ligand excluded by PLIPPEG.33: 3 residues within 4Å:- Chain A: Y.192, C.199
- Ligands: PEG.20
Ligand excluded by PLIPPEG.34: 1 residues within 4Å:- Chain A: F.206
Ligand excluded by PLIPPEG.35: 2 residues within 4Å:- Chain A: C.491, F.505
Ligand excluded by PLIPPEG.36: 1 residues within 4Å:- Ligands: OLC.13
Ligand excluded by PLIPPEG.37: 3 residues within 4Å:- Chain A: Y.92, N.96
- Ligands: PEG.17
Ligand excluded by PLIPPEG.38: 4 residues within 4Å:- Chain A: E.379, K.409, F.410, N.413
Ligand excluded by PLIPPEG.41: 5 residues within 4Å:- Chain A: C.440, A.443, I.444
- Ligands: OLA.4, OLC.12
Ligand excluded by PLIPPEG.42: 2 residues within 4Å:- Chain A: W.30, V.33
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Schoppe, J. et al., Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists. Nat Commun (2019)
- Release Date
- 2019-01-16
- Peptides
- Substance-P receptor,Substance-P receptor: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.20 Å
- Oligo State
- monomer
- Ligands
- 1 x GAW: 2-[3,5-bis(trifluoromethyl)phenyl]-~{N},2-dimethyl-~{N}-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide(Non-covalent)
- 1 x CIT: CITRIC ACID(Non-functional Binders)
- 9 x OLA: OLEIC ACID(Non-functional Binders)(Non-covalent)
- 7 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)
- 24 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Schoppe, J. et al., Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists. Nat Commun (2019)
- Release Date
- 2019-01-16
- Peptides
- Substance-P receptor,Substance-P receptor: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A - Membrane
-
We predict this structure to be a membrane protein.